138 related articles for article (PubMed ID: 17330105)
41. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro.
Akutsu M; Furukawa Y; Tsunoda S; Izumi T; Ohmine K; Kano Y
Leukemia; 2002 Sep; 16(9):1808-17. PubMed ID: 12200697
[TBL] [Abstract][Full Text] [Related]
42. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
43. miR-155 regulative network in FLT3 mutated acute myeloid leukemia.
Salemi D; Cammarata G; Agueli C; Augugliaro L; Corrado C; Bica MG; Raimondo S; Marfia A; Randazzo V; Dragotto P; Di Raimondo F; Alessandro R; Fabbiano F; Santoro A
Leuk Res; 2015 Aug; 39(8):883-96. PubMed ID: 26055960
[TBL] [Abstract][Full Text] [Related]
44. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Izumi T; Kobayashi H; Mano H; Furukawa Y
Invest New Drugs; 2007 Feb; 25(1):31-40. PubMed ID: 16865529
[TBL] [Abstract][Full Text] [Related]
45. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
Schlenk RF; Germing U; Hartmann F; Glasmacher A; Fischer JT; del Valle y Fuentes F; Götze K; Pralle H; Nerl C; Salwender H; Grimminger W; Petzer A; Hensel M; Benner A; Zick L; Döhner K; Fröhling S; Döhner H;
Leukemia; 2005 Jun; 19(6):978-83. PubMed ID: 15843821
[TBL] [Abstract][Full Text] [Related]
46. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
Li X; Wang A; Yu K; Qi Z; Chen C; Wang W; Hu C; Wu H; Wu J; Zhao Z; Liu J; Zou F; Wang L; Wang B; Wang W; Zhang S; Liu J; Liu Q
J Med Chem; 2015 Dec; 58(24):9625-38. PubMed ID: 26630553
[TBL] [Abstract][Full Text] [Related]
47. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; Griffin JD; Marynen P; Gilliland DG
Cancer Res; 2004 Sep; 64(18):6385-9. PubMed ID: 15374944
[TBL] [Abstract][Full Text] [Related]
48. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Schneider P; Nollau P; Horstmann M; Beverloo HB; van der Voort E; Valsecchi MG; de Lorenzo P; Sallan SE; Armstrong SA; Pieters R
Blood; 2005 Oct; 106(7):2484-90. PubMed ID: 15956279
[TBL] [Abstract][Full Text] [Related]
49. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
50. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
Yao Q; Nishiuchi R; Kitamura T; Kersey JH
Leukemia; 2005 Sep; 19(9):1605-12. PubMed ID: 16034464
[TBL] [Abstract][Full Text] [Related]
51. Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia.
de Vries AC; Stam RW; Schneider P; Niemeyer CM; van Wering ER; Haas OA; Kratz CP; den Boer ML; Pieters R; van den Heuvel-Eibrink MM
Haematologica; 2007 Nov; 92(11):1557-60. PubMed ID: 18024405
[TBL] [Abstract][Full Text] [Related]
52. [The present status of, and problems with the development of FLT3 kinase inhibitors].
Kiyoi H
Rinsho Ketsueki; 2006 Apr; 47(4):270-7. PubMed ID: 16715961
[No Abstract] [Full Text] [Related]
53. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
54. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.
Mohi MG; Boulton C; Gu TL; Sternberg DW; Neuberg D; Griffin JD; Gilliland DG; Neel BG
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3130-5. PubMed ID: 14976243
[TBL] [Abstract][Full Text] [Related]
55. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
Jin G; Matsushita H; Asai S; Tsukamoto H; Ono R; Nosaka T; Yahata T; Takahashi S; Miyachi H
Biochem Biophys Res Commun; 2009 Dec; 390(3):1001-6. PubMed ID: 19853583
[TBL] [Abstract][Full Text] [Related]
56. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.
Scholl S; Müller R; Clement JH; Loncarevic IF; Böhmer FD; Höffken K
Leuk Res; 2006 May; 30(5):633-42. PubMed ID: 16473406
[TBL] [Abstract][Full Text] [Related]
57. FLT3 as a therapeutic target in childhood acute leukemia.
Stubbs MC; Armstrong SA
Curr Drug Targets; 2007 Jun; 8(6):703-14. PubMed ID: 17584026
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia.
Lee JS; Wagner CB; Prelewicz S; Kurish HP; Walchack R; Cenin DA; Patel S; Lo M; Schlafer D; Li BKT; Donald Harvey Iii R; Wasef B; Ying J; Kovacsovics T
Haematologica; 2023 Dec; 108(12):3460-3463. PubMed ID: 37345485
[No Abstract] [Full Text] [Related]
59. FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia.
Perelló-Reus CM; Català A; Caviedes-Cárdenas L; Vega-García N; Camós M; Pérez-Torras S; Pastor-Anglada M
Pharmacol Res; 2020 Jan; 151():104556. PubMed ID: 31778791
[TBL] [Abstract][Full Text] [Related]
60. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
Gordon MJ; Tardi P; Loriaux MM; Spurgeon SE; Traer E; Kovacsovics T; Mayer LD; Tyner JW
Leuk Res; 2017 Feb; 53():39-49. PubMed ID: 28013106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
